MX2017015236A - Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation. - Google Patents

Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Info

Publication number
MX2017015236A
MX2017015236A MX2017015236A MX2017015236A MX2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A
Authority
MX
Mexico
Prior art keywords
acetylcysteine
glycine
supplementation
benefits
glutathione levels
Prior art date
Application number
MX2017015236A
Other languages
English (en)
Other versions
MX389285B (es
Inventor
Kirnon Stephen
Freedland Eric
V Sekhar Rajagopal
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2017015236A publication Critical patent/MX2017015236A/es
Publication of MX389285B publication Critical patent/MX389285B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones y métodos que se relacionan con el uso de glicina y N-acetilcisteína en una variedad de afecciones médicas relacionadas con niveles reducidos de glicina, N-acetilcisteína, y/o glutatión.
MX2017015236A 2015-05-28 2016-05-25 Beneficios de la suplementación con n-acetilcisteína y glicina para mejorar los niveles de glutatión. MX389285B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562167433P 2015-05-28 2015-05-28
PCT/US2016/034078 WO2016191468A1 (en) 2015-05-28 2016-05-25 Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels

Publications (2)

Publication Number Publication Date
MX2017015236A true MX2017015236A (es) 2018-11-09
MX389285B MX389285B (es) 2025-03-20

Family

ID=57393662

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017015236A MX389285B (es) 2015-05-28 2016-05-25 Beneficios de la suplementación con n-acetilcisteína y glicina para mejorar los niveles de glutatión.
MX2021014012A MX2021014012A (es) 2015-05-28 2017-11-27 Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014012A MX2021014012A (es) 2015-05-28 2017-11-27 Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Country Status (10)

Country Link
US (4) US10952982B2 (es)
EP (1) EP3302459A4 (es)
JP (4) JP7074663B6 (es)
CN (2) CN115957294A (es)
AU (1) AU2016268340B2 (es)
BR (1) BR112017025499A2 (es)
CA (1) CA2987597A1 (es)
MX (2) MX389285B (es)
TW (1) TWI769981B (es)
WO (1) WO2016191468A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115957294A (zh) * 2015-05-28 2023-04-14 贝勒医学院 补充n-乙酰半胱氨酸和甘氨酸以改善谷胱甘肽水平的有益效果
US20210315792A1 (en) * 2016-10-18 2021-10-14 Somahlution, Llc Dermatological compositions for providing nutrients to skin and methods thereof
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
WO2019101700A1 (en) * 2017-11-21 2019-05-31 Nestec S.A. Compositions and methods using oleuropein or curcumin for muscle quality and/or muscle mass
KR102860981B1 (ko) 2018-02-09 2025-09-18 데시벨 테라퓨틱스, 인크. 항-백금 화학보호제를 함유하는 고장성 약제학적 조성물
US20210228484A1 (en) * 2018-04-19 2021-07-29 Daniel BIDNER Veterinary thick gel composition of high palatability containing antioxidants to decrease sarcopenia, osteopenia and dna damage from oxidative stress in dogs, and procedure for its obtention
IT201800006566A1 (it) * 2018-06-21 2019-12-21 Composizione per prevenire e trattare disordini uditivi e vestibolari
US20210267251A1 (en) * 2018-06-21 2021-09-02 Societe Des Produits Nestle S.A. Compositions and methods using a nicotinamide adenine dinucleotide (nad+) precursor and at least one ketone or ketone precursor
US11974975B2 (en) 2018-09-27 2024-05-07 Societe Des Produits Nestle S.A. Compositions and methods using at least one glycine or derivative thereof, at least one N-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or NAD+ precursor
CN112752575A (zh) 2018-09-27 2021-05-04 雀巢产品有限公司 组氨酸、甘氨酸和其它氨基酸用于预防胰岛素抗性和/或糖尿病的用途
JP7542530B2 (ja) * 2018-11-02 2024-08-30 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 緩衝塩及びアミノ酸を含有する粉末、そのような粉末の栄養製品への再構成、並びにそのような栄養製品を使用する方法
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
EP3756648A1 (en) * 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations
CN114302718A (zh) * 2019-06-28 2022-04-08 有机合成药品工业株式会社 线粒体功能活化剂
CN110152004B (zh) * 2019-07-08 2021-09-03 天津医科大学 甘氨酸在制备药物递送增强剂及细胞移植试剂方面的用途
US11717554B2 (en) * 2019-09-19 2023-08-08 Max R&D Llc Method for preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s)
CA3158912A1 (en) * 2019-11-18 2021-05-27 Societe Des Produits Nestle S.A. Compositions and methods for glutathione enhancement for use in brain health
CN115484945A (zh) 2019-12-18 2022-12-16 纽罗内泽尔公司 治疗脑病症的方法
WO2021198399A1 (en) * 2020-04-01 2021-10-07 Société des Produits Nestlé S.A. Compositions and methods containing n-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions
CN115397261A (zh) * 2020-04-29 2022-11-25 雀巢产品有限公司 含有缓冲剂组合物和氨基酸的营养产品以及使用这种营养产品的方法
US20210369661A1 (en) * 2020-05-27 2021-12-02 Immunoflex Therapeutics Inc. Methods and compositions for treating and recovering from viral infections
CN116546981A (zh) * 2020-12-18 2023-08-04 雀巢产品有限公司 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
MX2024006265A (es) * 2021-12-02 2024-06-11 Nestle Sa Composiciones y metodos que usan una mezcla de aminoacidos para proporcionar un beneficio de salud en un animal.
CN118973613A (zh) * 2022-01-25 2024-11-15 早野元词 抑制包括肌肉减少症的与衰老相关的异常的新型治疗与预防
WO2023158505A1 (en) * 2022-02-16 2023-08-24 Prothione Llc Compositions and methods for the treatment of human immunodeficiency virus
AU2023378253A1 (en) * 2022-11-07 2025-04-24 Société des Produits Nestlé S.A. Compositions and methods using glycine to reduce biological age of an adult animal
GB202311877D0 (en) * 2023-08-02 2023-09-13 Mars Inc Companion animal supplementation
US12458686B1 (en) 2025-04-02 2025-11-04 Goa Therapeutics Corporation Compositions and methods for reducing blood ethanol concentration through alcohol dehydrogenase and acetaldehyde scavengers

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792110A (en) * 1996-06-26 1998-08-11 Cunningham; Miles G. Systems and methods for delivering therapeutic agents to selected sites in a subject
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1999043697A1 (en) * 1998-02-25 1999-09-02 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
US7351427B2 (en) * 1998-06-18 2008-04-01 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
EP1381373B1 (en) 2001-04-25 2006-06-14 Cobalz Limited Medical compositions for use in the treatment or prevention of a functional vitamin b12 deficienfcy
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
US20040120983A1 (en) * 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
CA2454749A1 (en) * 2002-12-31 2004-06-30 Glen A. Gordon Method and apparatus for pulsed electromagnetic therapy
US8697679B2 (en) * 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
EP1706146B1 (en) * 2003-12-31 2013-08-21 K-Pax Pharmaceuticals, Inc. Nutrient compositions and use thereof for enhanced effectiveness of the immune system
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
US20060160721A1 (en) * 2004-12-22 2006-07-20 Baylor College Of Medicine Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US7754700B2 (en) * 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
CA2667052A1 (en) * 2006-10-23 2008-05-02 The Mental Health Research Institute Of Victoria Combination therapy
MX2010009290A (es) * 2008-02-29 2010-09-14 Biolab Sanus Farmaceutica Ltda Composicion farmaceutica.
EP2189453A1 (en) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
US8362080B2 (en) * 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
CA2679784A1 (en) * 2009-03-05 2010-09-05 Newcastle Innovation Limited Diagnostic, prognostic and treatment methods
US20110104137A1 (en) * 2009-04-21 2011-05-05 Chronorx Llc, An Alaska Limited Liability Company ADJUNCTS AND COMPLEXES FOR IMPROVING HMG-CoA REDUCTASE INHIBITOR (STATIN) AND SELECTIVE PHOSPHODIESTERASE 5 INHIBITOR THERAPY
US8796315B2 (en) * 2009-06-25 2014-08-05 Darlene E. McCord Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells
WO2011087548A2 (en) * 2009-10-27 2011-07-21 William Marsh Rice University Therapeutic compositions and methods for targeted delivery of active agents
EP3248609B1 (en) * 2011-10-28 2019-10-16 NeoStrata Company, Inc. N-acyldipeptide derivatives and their uses
WO2013072714A1 (en) * 2011-11-15 2013-05-23 Centre National De La Recherche Scientifique (Cnrs) Antibodies for molecular imaging of vulnerable plaques in atherosclerosis
JP5918395B2 (ja) * 2012-02-07 2016-05-18 ゼノポート，インコーポレイティド モルホリノアルキルフマレート化合物、医薬組成物及び使用方法
US20140006042A1 (en) * 2012-05-08 2014-01-02 Richard Keefe Methods for conducting studies
US8747894B2 (en) * 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
WO2014011676A1 (en) * 2012-07-09 2014-01-16 Tolleth Robert J Prevention of alcohol reaction with dietary supplements
US9144555B2 (en) * 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
US20150216237A1 (en) * 2014-01-22 2015-08-06 E-Nicotine Technology, Inc. Methods and devices for smoking urge relief
CA2944560A1 (en) * 2014-04-08 2015-10-15 Eskil Elmer Prodrugs of succinic acid for increasing atp production
WO2016007581A1 (en) * 2014-07-09 2016-01-14 Mccord Darlene E Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition
US20170281713A1 (en) * 2014-08-29 2017-10-05 Albert B. Crum A method for side effect reduction in the use of statins via physiologically synthesized glutathione
US20160302451A1 (en) * 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
CN115957294A (zh) * 2015-05-28 2023-04-14 贝勒医学院 补充n-乙酰半胱氨酸和甘氨酸以改善谷胱甘肽水平的有益效果

Also Published As

Publication number Publication date
JP2023022033A (ja) 2023-02-14
JP2021073181A (ja) 2021-05-13
TWI769981B (zh) 2022-07-11
US20210244696A1 (en) 2021-08-12
US20240041812A1 (en) 2024-02-08
AU2016268340B2 (en) 2021-07-08
US20180161297A1 (en) 2018-06-14
EP3302459A4 (en) 2019-02-20
JP2018516280A (ja) 2018-06-21
US10952982B2 (en) 2021-03-23
CN115957294A (zh) 2023-04-14
CN107847475A (zh) 2018-03-27
WO2016191468A1 (en) 2016-12-01
AU2016268340A1 (en) 2017-11-30
US20230137543A1 (en) 2023-05-04
TW201707696A (zh) 2017-03-01
JP7074663B6 (ja) 2022-08-01
US12186292B2 (en) 2025-01-07
CA2987597A1 (en) 2016-12-01
JP7074663B2 (ja) 2022-05-24
JP2025003996A (ja) 2025-01-14
MX389285B (es) 2025-03-20
JP7629432B2 (ja) 2025-02-13
MX2021014012A (es) 2022-01-06
EP3302459A1 (en) 2018-04-11
US11730711B2 (en) 2023-08-22
BR112017025499A2 (pt) 2018-08-07

Similar Documents

Publication Publication Date Title
MX2021014012A (es) Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
CL2017002161A1 (es) Jarabes de alulosa
BR112016024494A8 (pt) análogo de peptídeo e seu uso
MX386418B (es) Composicion acida que comprende una ficocianina.
MX2019011496A (es) Composiciones de niraparib.
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
EA201790722A1 (ru) КОМПОЗИЦИЯ С НИЗКИМ pH, СОДЕРЖАЩАЯ КОНКРЕТНЫЕ КОНСЕРВАЦИОННЫЕ СИСТЕМЫ
BR112018007356A2 (pt) métodos de produção de formas fucosiladas e não fucosiladas de uma proteína
MX2016012530A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
BR112016006048A8 (pt) composições antimicrobianas
CL2020000897A1 (es) Composición de proteínas de guisante que tiene calidad nutricional mejorada.
MX2017008277A (es) Solucion oftalmica acuosa.
BR112017013770A2 (pt) composições de inibidor de nitrificação microencapsuladas
MX2018016037A (es) Variantes de lipasa y composiciones que comprenden tensioactivo y variante de lipasa.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
AU357379S (en) Low profile pump
MX2018007871A (es) Composiciones para el cuidado personal.
BR112017012818A2 (pt) fixador.
UY36107A (es) Composición microencapsulada inhibidora de la nitrificación
MX2018000634A (es) Nueva especie de tobamovirus.
AR104591A1 (es) Piroglutamato de vortioxetina